Display options
Cite
John S, Natarajan S, Parikumar P, et al. Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to Age-Related Macular Degeneration: A Review. J Ophthalmol. 2013;2013:465169doi: 10.1155/2013/465169.
John, S., Natarajan, S., Parikumar, P., Shanmugam P, M., Senthilkumar, R., Green, D. W., & Abraham, S. J. (2013). Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to Age-Related Macular Degeneration: A Review. Journal of ophthalmology, 2013465169. https://doi.org/10.1155/2013/465169
John, Sudhakar, et al. "Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to Age-Related Macular Degeneration: A Review." Journal of ophthalmology vol. 2013 (2013): 465169. doi: https://doi.org/10.1155/2013/465169
John S, Natarajan S, Parikumar P, Shanmugam P M, Senthilkumar R, Green DW, Abraham SJ. Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to Age-Related Macular Degeneration: A Review. J Ophthalmol. 2013;2013:465169. doi: 10.1155/2013/465169. Epub 2013 Apr 22. PMID: 23710332; PMCID: PMC3654320.
Copy Download .nbib Format: NLM
Share it on

J Ophthalmol. 2013;2013:465169. doi: 10.1155/2013/465169. Epub 2013 Apr 22.

Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to Age-Related Macular Degeneration: A Review.

Journal of ophthalmology

Sudhakar John, Sundaram Natarajan, Periyasamy Parikumar, Mahesh Shanmugam P, Rajappa Senthilkumar, David William Green, Samuel J K Abraham

Affiliations

  1. The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), P.O. Box 1262, Nungambakkam, Chennai 600034, India.

PMID: 23710332 PMCID: PMC3654320 DOI: 10.1155/2013/465169

Abstract

Background. Age-related macular degeneration (AMD) is a complex disorder that affects primarily the macula involving the retinal pigment epithelium (RPE) but also to a certain extent the photoreceptor layer and the retinal neurons. Cell transplantation is a promising option for AMD and clinical trials are underway using different cell types. Methods. We hypothesize that instead of focusing on a particular cell source for concurrent regeneration of all the retinal layers and also to prevent exhaustive research on an array of cell sources for regeneration of each layer, the choice should depend on, precisely, which layer is damaged. Results. Thus, for a damage limited to the retinal pigment epithelial (RPE) layer, the choice we suggest would be RPE cells. When the damage extends to rods and cones, the choice would be bone marrow stem cells and when retinal neurons are involved, relatively immature stem cell populations with an inherent capacity to yield neuronal lineage such as hematopoietic stem cells, embryonic stem cells, or induced pluripotent stem cells can be tried. Conclusion. This short review will prove to be a valuable guideline for those working on cell therapy for AMD to plan their future directions of research and therapy for this condition.

References

  1. J Clin Invest. 2004 Sep;114(6):765-74 - PubMed
  2. Neuroscience. 2005;133(1):85-95 - PubMed
  3. Am J Ophthalmol. 2002 Feb;133(2):215-25 - PubMed
  4. Invest Ophthalmol Vis Sci. 1987 Jul;28(7):1131-7 - PubMed
  5. Wideochir Inne Tech Maloinwazyjne. 2012 Aug;7(3):220-3 - PubMed
  6. Stem Cells. 2011 May;29(5):825-35 - PubMed
  7. Invest Ophthalmol Vis Sci. 1992 Jan;33(1):83-91 - PubMed
  8. Vision Res. 1996 Dec;36(24):4121-5 - PubMed
  9. J Med Assoc Thai. 2011 Mar;94(3):395-400 - PubMed
  10. PLoS One. 2011 Apr 29;6(4):e18992 - PubMed
  11. Folia Histochem Cytobiol. 2005;43(4):233-5 - PubMed
  12. Cell Stem Cell. 2012 Jan 6;10(1):88-95 - PubMed
  13. Cell Transplant. 2008;17(12):1277-93 - PubMed
  14. Graefes Arch Clin Exp Ophthalmol. 2011 Oct;249(10):1439-48 - PubMed
  15. Health Qual Life Outcomes. 2006 Dec 21;4:97 - PubMed
  16. Graefes Arch Clin Exp Ophthalmol. 1997 Mar;235(3):149-58 - PubMed
  17. Eye (Lond). 2008 Jun;22(6):799-807 - PubMed
  18. Graefes Arch Clin Exp Ophthalmol. 2010 Jan;248(1):37-47 - PubMed
  19. Trends Neurosci. 1992 Mar;15(3):103-8 - PubMed
  20. Exp Eye Res. 1988 Dec;47(6):911-7 - PubMed
  21. J Genet. 2009 Dec;88(4):425-49 - PubMed
  22. Nature. 2012 May 3;485(7396):99-103 - PubMed
  23. Arq Bras Oftalmol. 2010 Sep-Oct;73(5):474-9 - PubMed
  24. J Comp Neurol. 2010 Feb 15;518(4):526-46 - PubMed
  25. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5227-32 - PubMed
  26. Am J Pathol. 2006 Mar;168(3):1031-44 - PubMed
  27. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4151-60 - PubMed
  28. Ophthalmology. 2002 Aug;109(8):1492-8 - PubMed
  29. Arq Bras Oftalmol. 2008 Mar-Apr;71(2):246-53 - PubMed
  30. Invest Ophthalmol Vis Sci. 2001 Mar;42(3):795-803 - PubMed
  31. J Neurosci. 2003 Aug 27;23(21):7742-9 - PubMed
  32. Ophthalmic Res. 2012;48 Suppl 1:1-5 - PubMed
  33. Acta Ophthalmol. 2010 Jun;88(4):e131-2 - PubMed
  34. Int J Ophthalmol. 2011;4(5):466-73 - PubMed
  35. Arch Ophthalmol. 2004 Apr;122(4):564-72 - PubMed
  36. Ophthalmic Surg. 1991 Feb;22(2):102-8 - PubMed
  37. Indian J Exp Biol. 2010 May;48(5):444-52 - PubMed
  38. Stem Cells. 2009 Jun;27(6):1376-87 - PubMed
  39. Growth. 1959 Dec;23:313-36 - PubMed
  40. Br J Ophthalmol. 2011 Mar;95(3):370-5 - PubMed
  41. Dev Neurosci. 2001;23(4-5):268-76 - PubMed
  42. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5970-8 - PubMed
  43. Stem Cell Rev Rep. 2011 Jun;7(2):434-45 - PubMed
  44. Clin Ophthalmol. 2009;3:155-66 - PubMed
  45. Stem Cells. 2006 Oct;24(10):2292-8 - PubMed
  46. J Cell Biochem. 2010 Oct 1;111(2):249-57 - PubMed
  47. Stem Cells. 2009 Oct;27(10):2427-34 - PubMed
  48. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6537-42 - PubMed
  49. Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1236-49 - PubMed
  50. Curr Opin Investig Drugs. 2006 Jan;7(1):18-9 - PubMed
  51. Dev Biol. 2007 Mar 1;303(1):45-56 - PubMed
  52. Br J Ophthalmol. 2004 Jan;88(1):110-3 - PubMed
  53. Br J Ophthalmol. 2011 Apr;95(4):441-2 - PubMed
  54. Stem Cells. 2002;20(4):279-83 - PubMed
  55. Nature. 2011 May 13;474(7350):212-5 - PubMed
  56. Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):354-9 - PubMed
  57. Arch Ophthalmol. 2002 Dec;120(12):1714-8 - PubMed
  58. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2088-93 - PubMed
  59. Exp Neurol. 2000 Aug;164(2):247-56 - PubMed
  60. BMJ. 2003 Mar 1;326(7387):485-8 - PubMed
  61. Acta Ophthalmol. 2008 Mar;86(2):225-6 - PubMed
  62. Arq Bras Oftalmol. 2009 Jan-Feb;72(1):123-30 - PubMed
  63. Mol Vis. 2008;14:2309-20 - PubMed
  64. J Control Release. 2013 Apr 10;167(1):21-8 - PubMed
  65. Expert Opin Biol Ther. 2010 Aug;10(8):1227-39 - PubMed
  66. Invest Ophthalmol Vis Sci. 1995 Feb;36(2):381-90 - PubMed
  67. Am J Ophthalmol. 2006 Jul;142(1):17-30 - PubMed
  68. J Hematother Stem Cell Res. 2003 Dec;12(6):727-34 - PubMed
  69. Clin Exp Ophthalmol. 2009 Apr;37(3):275-85 - PubMed
  70. Prog Retin Eye Res. 2007 Sep;26(5):516-54 - PubMed

Publication Types